The pathogenesis of acute pulmonary viral and bacterial infections: Investigations in animal models

Annual Review of Pathology: Mechanisms of Disease

Volumn 5, Issue , 2010, Pages 223-252

  Lipscomb, Mary F ^a   Hutt, Julie ^a,b   Lovchik, Julie ^a   Wu, Terry ^a   Lyons, C Rick ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

Author keywords

Animal models; Bacillus anthracis; Francisella tularensis; Orthopoxviruses; Pulmonary immunology

Indexed keywords

ANTHRAX TOXIN; ANTHRAX VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLUENZA VACCINE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17F; INTERLEUKIN 4; INTERLEUKIN 8; LIVE VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; ORTHOPOXVIRUS VACCINE;

ADAPTIVE IMMUNITY; ADENOVIRUS; ANTHRAX; BACILLUS ANTHRACIS; BACTERIAL INFECTION; CD4+ CD25+ T LYMPHOCYTE; CHLAMYDOPHILA PNEUMONIAE; CLINICAL STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; DENDRITIC CELL; EXPERIMENTAL MODEL; FRANCISELLA TULARENSIS; HAEMOPHILUS INFLUENZAE; HERPES SIMPLEX VIRUS; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INFLUENZA; INFLUENZA VIRUS; INNATE IMMUNITY; LEGIONELLA PNEUMOPHILA; LOWER RESPIRATORY TRACT INFECTION; MORBIDITY; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; NATURAL KILLER CELL; NONHUMAN; ORTHOPOXVIRUS; PARAINFLUENZA VIRUS; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSICIAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SCIENTIST; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; ACTIVE IMMUNIZATION; ANIMAL; DISEASE MODEL; IMMUNOLOGY; MACACA; MICROBIOLOGY; MOUSE; RABBIT; RAT; RESPIRATORY TRACT INFECTION; VIROLOGY;

ADAPTIVE IMMUNITY; ANIMALS; DISEASE MODELS, ANIMAL; IMMUNITY, INNATE; IMMUNOTHERAPY, ACTIVE; MACACA FASCICULARIS; MICE; RABBITS; RATS; RESPIRATORY TRACT INFECTIONS;

EID: 77949907983     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-121808-102153     Document Type: Review

References (168)

1. Mizgerd JP. 2008. Acute lower respiratory tract infection. N. Engl. J. Med. 358:716-727
2. Ostapchuk M, Roberts DM, Haddy R. 2004. Community-acquired pneumonia in infants and children. Am. Fam. Physician 70:899-908
3. Scott JA, Brooks WA, Peiris JS, Holtzman D, Mulhollan EK. 2008. Pneumonia research to reduce childhood mortality in the developing world. J. Clin. Investig. 118:1291-1300
4. Lipscomb MF, Bice DE, Lyons CR, Schuyler MR, Wilkes D. 1995. The regulation of pulmonary immunity. Adv. Immunol. 59:369-455
5. Colebatch HJ, Ng CK. 1992. Estimating alveolar surface area during life. Respir. Physiol. 88:163-170
6. Hasleton PS. 1972. The internal surface area of the adult human lung. J. Anat. 112:391-400
7. Kikuchi R,Watabe N, Konno T, Mishina N, Sekizawa K, Sasaki H. 1994. High incidence of silent aspiration in elderly patients with community-acquired pneumonia. Am. J. Respir. Crit. Care Med. 150:251-253
8. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. 2007. Interleukins 1? and 6 but not transforming growth factor-? are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 8:942-949
9. Holt PG, Strickland DH,Wikstrom ME, Jahnsen FL. 2008. Regulation of immunological homeostasis in the respiratory tract. Nat. Rev. Immunol. 8:142-152
10. Lambrecht BN, Prins JB, Hoogsteden HC. 2001. Lung dendritic cells and host immunity to infection. Eur. Respir. J. 18:692-704
11. Tsai KS, Grayson MH. 2008. Pulmonary defense mechanisms against pneumonia and sepsis. Curr. Opin. Pulm. Med. 14:260-265
12. Pastva AM, Wright JR, Williams KL. 2007. Immunomodulatory roles of surfactant proteins A and D: implications in lung disease. Proc. Am. Thorac. Soc. 4:252-257
13. Strowig T, Brilot F, Munz C. 2008. Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity. J. Immunol. 180:7785-7791
14. Cerundolo V, Silk JD, Masri SH, Salio M. 2009. Harnessing invariantNKTcells in vaccination strategies. Nat. Rev. Immunol. 9:28-38
15. Malaviya R, Abraham SN. 2001. Mast cell modulation of immune responses to bacteria. Immunol. Rev. 179:16-24
16. Marshall JS. 2004. Mast-cell responses to pathogens. Nat. Rev. Immunol. 4:787-799
17. Galli SJ, Nakae S, Tsai M. 2005. Mast cells in the development of adaptive immune responses. Nat. Rev. Immunol. 6:135-142
18. Galli SJ, Grimbaldeston M, Tsai M. 2008. Immunoregulatory mast cells: negative, as well as positive, regulators of immunity. Nat. Rev. Immunol. 8:478-486
19. Nakahira K, Kim HP, Geng XH, Nakao A,Wang X, et al. 2006. Carbon monoxide differentially inhibits TLR signaling pathways by regulating ROS-induced trafficking of TLRs to lipid rafts. J. Exp. Med. 203:2377-2389
20. Bettelli E, Oukka M, Kuchroo VK. 2007. T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 8:345-350
21. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, et al. 2007. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat. Immunol. 8:369-377
22. Bice DE, Degen MA, Harris DL, Muggenburg BA. 1982. Recruitment of antibody-forming cells in the lung after local immunization is nonspecific. Am. Rev. Respir. Dis. 126:635-639
23. Bice DE, Weissman DN, Muggenburg BA. 1991. Long-term maintenance of localized antibody responses in the lung. Immunology 74:215-222
24. Tang Q, Bluestone JA. 2008. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat. Immunol. 9:239-244
25. Bluestone JA, Abbas AK. 2003. Natural versus adaptive immunity. Nat. Rev. Immunol. 33:253-257
26. Nguyen KD, Fohner A, Booker JD, Dong C, Krensky AM,Nadeau KC. 2008.XCL1enhances regulatory activities of CD4+ CD25(high) CD127(low/?) T cells in human allergic asthma. J. Immunol. 181:5386-5395
27. Umetsu DT, DeKruyff RH. 2006. The regulation of allergy and asthma. Immunol. Rev. 212:238-255
28. Xystrakis E, Urry Z, Hawrylowicz CM. 2007. Regulatory T cell therapy as individualized medicine for asthma and allergy. Curr. Opin. Allergy Clin. Immunol. 7:535-541
29. Lipscomb M, Wilder J, Masten B. 2007. DC and their role in linking innate and adaptive immune responses. In The Biology of Dendritic Cells and HIV Infection, ed. S Gessani, F Belardelli, pp. 45-84. New York: Springer
30. Lipscomb MF, Masten BJ. 2002. Dendritic cells: immune regulators in health and disease. Physiol. Rev. 82:97-130
31. Sanchez-Sanchez N, Riol-Blanco L, Rodriguez-Fernandez JL. 2006. The multiple personalities of the chemokine receptor CCR7 in dendritic cells. J. Immunol. 176:5153-5159
32. del Rio ML, Rodriguez-Barbosa JI, Kremmer E, Forster R. 2007. CD103- and CD103+bronchial lymph node dendritic cells are specialized in presenting and cross-presenting innocuous antigen to CD4+ and CD8+ T cells. J. Immunol. 178:6861-6866
33. van Rijt LS, Jung S, Kleinjan A,VosN,Willart M, et al. 2005. In vivo depletion of lung CD11c+dendritic cells during allergen challenge abrogates the characteristic features of asthma. J. Exp. Med. 201:981-991
34. Demedts IK, Bracke KR, Maes T, Joos GF, Brusselle GG. 2006. Different roles for human lung dendritic cell subsets in pulmonary immune defense mechanisms. Am. J. Respir. Cell Mol. Biol. 35:387-393
35. Demedts IK, Brusselle GG, Vermaelen KY, Pauwels RA. 2005. Identification and characterization of human pulmonary dendritic cells. Am. J. Respir. Cell Mol. Biol. 32:177-184
36. Masten BJ, Olson GK, Tarleton CA, Rund C, Schuyler M, et al. 2006. Characterization of myeloid and plasmacytoid dendritic cells in human lung. J. Immunol. 177:7784-7793
37. Ito T, Amakawa R, Inaba M, Hori T, Ota M, et al. 2004. Plasmacytoid dendritic cells regulate Th cell responses through OX40 ligand and type I IFNs. J. Immunol. 172:4253-4259
38. Kadowaki N, Antonenko S, Lau JY, Liu YJ. 2000. Natural interferon -producing cells link innate and adaptive immunity. J. Exp. Med. 192:219-226
39. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. 2005. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6:769-776
40. Shakhar G,Lindquist RL,Skokos D,Dudziak D,Huang JH,et al.,2005,Stable T cell-dendritic cell interactions precede the development of both tolerance and immunity in vivo. Nat. Immunol, 6,707-7,14
41. Vivier E, Malissen B. 2005. Innate and adaptive immunity: specificities and signaling hierarchies revisited. Nat. Immunol. 6:17-21
42. von Boehmer H. 2005. Mechanisms of suppression by suppressor T cells. Nat. Immunol. 6:338-344
43. Awasthi A, Carrier Y, Peron JP, Bettelli E, Kamanaka M, et al. 2007. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat. Immunol. 8:1380-1389
44. Fitzgerald DC, Zhang GX, El-Behi M, Fonseca-Kelly Z, Li H, et al. 2007. Suppression of autoimmune inflammation of thecentral nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat. Immunol. 8:1372-1379
45. Jankovic D, Trinchieri G. 2007. IL-10 or not IL-10: That is the question. Nat. Immunol. 8:1281-1283
46. McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, et al. 2007. TGF- and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat. Immunol. 8:1390-1397
47. Stumhofer JS, Silver JS, Laurence A, Porrett PM, Harris TH, et al. 2007. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat. Immunol. 8:1363-1371
48. Virgin HW. 2007. In vivo veritas: pathogenesis of infection as it actually happens. Nat. Immunol. 8:1143-1147
49. Mizgerd JP, Skerrett SJ. 2008. Animal models of human pneumonia. Am. J. Physiol. Lung. Cell Mol. Physiol. 294:L387-398
50. Fang FC. 2004. Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nat. Rev. Microbiol. 2:820-832
51. Perl AK, Zhang L, Whitsett JA. 2009. Conditional expression of genes in the respiratory epithelium in transgenic mice: cautionary notes and toward building a better mouse trap. Am. J. Respir. Cell Mol. Biol. 40:1-3
52. Treanor J. 2005. Influenza virus. In Mandell, Douglas, and Bennett's Principle and Practice of Infectious Diseases, ed. G Mandell, J Bennett, R Dolin, pp. 2060-2085 Philadelphia: Elsievier. 6th ed.
53. Smith W, Andrew CH, Laidlaw P. 1933. A virus obtained from influenza patients. Lancet 225:66-68
54. Frankova V. 1975. Inhalatory infection of mice with influenza A0Pr8 virus. I. The site of primary virus replication and its spread in the respiratory tract. Acta Virol. 19:29-34
55. Zambon MC. 2001. The pathogenesis of influenza in humans. Rev. Med. Virol. 11:227-241
56. Chen H, Bright RA, Subbarao K, Smith C, Cox NJ, et al. 2007. Polygenic virulence factors involved in pathogenesis of1997 Hong Kong H5N1 influenza viruses in mice. Virus Res. 128(1-2):159-163
57. Couch RB, Kasel JA. 1983. Immunity to influenza in man. Annu. Rev. Microbiol. 37:529-549
58. Clements ML,Betts RF,Tierney EL,Murphy BR, 1986, Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J. Clin. Microbiol, 24,157-160
59. Whimbey E, Elting LS, Couch RB, Lo W,Williams L, et al. 1994. Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transpl. 13:437-440
60. Taubenberger JK, Morens DM. 2008. The pathology of influenza virus infections. Annu. Rev. Pathol. Mech. Dis. 3:499-522
61. Lund FE, Partida-Sanchez S, Lee BO, Kusser KL, Hartson L, et al. 2002. Lymphotoxin-?-deficient mice make delayed, but effective, T and B cell responses to influenza. J. Immunol. 169:5236-5243
62. Moyron-Quiroz JE, Rangel-Moreno J, Kusser K, Hartson L, Sprague F, et al. 2004. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat. Med. 10:927-934
63. Rangel-Moreno J, Moyron-Quiroz JE, Hartson L, Kusser K, Randall TD. 2007. Pulmonary expression of CXC chemokine ligand 13, CC chemokine ligand 19, and CC chemokine ligand 21 is essential for local immunity to influenza. Proc. Natl. Acad. Sci. USA 104:10577-10582
64. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, et al. 2006. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 12:1203-1207
65. Kobasa D, Jones SM, Shinya K, Kash JC, Copps J, et al. 2007. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445:319-323
66. Snelgrove RJ, Goulding J, Didierlaurent AM, Lyonga D, Vekaria S, et al. 2008. A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat. Immunol. 9:1074-1083
67. Damon I. 2005. Orthopoxviruses: vaccinia (smallpox vaccine), variola (smallpox), monkeypox, and cowpox. In Mandell, Douglas, and Bennett's Principle and Practice of Infectious Diseases, ed.GMandell, J Bennett, R Dolin, pp. 1742-1751 Philadelphia: Elsievier. 6th ed.
68. Moss B. 2001. Poxviridae: the viruses and their replication. In Fields Virology, ed. D Knipe, P Howley, pp. 2849-2883 Philidelphia: Lippincott,Williams &Wilkins
69. Henderson DA. 1999. Smallpox: clinical and epidemiologic features. Emerg. Infect. Dis. 5:537-539
70. Baxby D, Bennett M, Getty B. 1994. Human cowpox 1969-93: a review based on 54 cases. Br. J. Dermatol. 131:598-607
71. Scarff D, Clough C. 1990. Fatal cowpox infection in a human. Vet. Rec. 127:459
72. Vestergaard L, Vinner L, Andersen KE, Fomsgaard A. 2008. Identification of cowpox infection in a 13-year-old Danish boy. Acta Derm. Venereol. 88:188-190
73. Vorou RM, Papavassiliou VG, Pierroutsakos IN. 2008. Cowpox virus infection: an emerging health threat. Curr. Opin. Infect. Dis. 21:153-156
74. Di Giulio DB, Eckburg PB. 2004. Human monkeypox: an emerging zoonosis. Lancet Infect. Dis. 4:15-25
75. Reed KD, Melski JW, Graham MB, Regnery RL, Sotir MJ, et al. 2004. The detection of monkeypox in humans in theWestern Hemisphere. N. Engl. J. Med. 350:342-350
76. Alcami A. 2007. New insights into the subversion of the chemokine system by poxviruses. Eur. J. Immunol. 37:880-883
77. Haga IR, Bowie AG. 2005. Evasion of innate immunity by vaccinia virus. Parasitology 130(Suppl.):S11-25
78. Pickup DJ. 1994. Poxviral modifiers of cytokine responses to infection. Infect. Agents Dis. 3:116-127
79. Pickup DJ. 2007. Understanding orthopoxvirus interference with host immune responses to inform novel vaccine design. Expert Rev. Vaccines 6:87-95
80. McFadden G. 2005. Poxvirus tropism. Nat. Rev. Microbiol. 3:201-213
81. Sanchez-Puig JM, Sanchez L, Roy G, Blasco R. 2004. Susceptibility of different leukocyte cell types to vaccinia virus infection. Virol. J. 1:10
82. Alcami A, Symons JA, Collins PD, Williams TJ, Smith GL. 1998. Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. J. Immunol. 160:624-633
83. Saraiva M, Alcami A. 2001. CrmE, a novel soluble tumor necrosis factor receptor encoded by poxviruses. J. Virol. 75:226-233
84. Thompson JP,Turner PC, Ali AN, Crenshaw BC, MoyerRW. 1993. The effects of serpin gene mutations on the distinctive pathobiology of cowpox and rabbitpox virus following intranasal inoculation of Balb/c mice. Virology 197:328-338
85. Kotwal G, Moss B. 1988. Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature 335:176-178
86. Miller CG, Shchelkunov SN, Kotwal GJ. 1997. The cowpox virus-encoded homolog of the vaccinia virus complement control protein is an inflammation modulatory protein. Virology 229:126-133
87. Pickup D, Ink B, Hu W, Ray C, Joklik W. 1986. Hemorrhage in lesions caused by cowpox virus is induced by a viral protein that is related to plasma protein inhibitors of serine proteases. Proc. Natl. Acad. Sci. USA 83:7698-7702
88. Quan LT, Caputo A, Bleackley RC, Pickup DJ, Salvesen GS. 1995. Granzyme B is inhibited by the cowpox virus serpin cytokine response modifier A. J. Biol. Chem. 270:10377-10379
89. Ray CA, Black RA, Kronheim SR, Greenstreet TA, Sleath PR, et al. 1992. Viral inhibition of inflammation: Cowpox virus encodes an inhibitor of the interleukin-1 converting enzyme. Cell 69:597-604
90. Zhou Q, Snipas S, Orth K, Muzio M, Dixit VM, Salvesen GS. 1997. Target protease specificity of the viral serpin CrmA. Analysis of five caspases. J. Biol. Chem. 272:7797-7800
91. Chang H,Watson J, Jacobs B. 1992. TheE3Lgene of vaccinia virus encodes an inhibitor of the interferoninduced, double stranded RNA-dependent protein kinase. Proc. Natl. Acad. Sci. USA 89:4825-4829
92. Davies M, Chang H, Jacobs B, Kaufman R. 1993. The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms. J. Virol. 67:1688-1692
93. Comeau M, Johnson R, DuBose R, Petersen M, Gearing P, et al. 1998. A poxvirus-encoded semaphorin induces cytokine production from monocytes and binds to a novel cellular semaphorin receptor, VESPR. Immunity 8:473-482
94. Bowie A, Kiss-Toth E, Symons J, Smith G, Dower S, O'Neill L. 2000. A46R and A52R from vaccinia virus are antagonists of host IL-1 and Toll-like receptor signaling. Proc. Natl. Acad. Sci. USA 97:10162-10167
95. Najarro P, Traktman P, Lewis J. 2001. Vaccinia virus blocks- interferon signal transduction: Viral VH1 phosphatase reverses Stat 1 activation. J. Virol. 75:3185-3196
96. Mann BA, Huang JH, Li P, Chang HC, Slee RB, et al. 2008. Vaccinia virus blocks Stat1-dependent and Stat1-independent gene expression induced by type I and type II interferons. J. Interf. Cytokine Res. 28:367-380
97. Oie KL, Pickup DJ. 2001. Cowpox virus and other members of the orthopoxvirus genus interfere with the regulation of NF-B activation. Virology 288:175-187
98. Spriggs MK, Hruby DE, Maliszewski CR, Pickup DJ, Sims JE, et al. 1992. Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein. Cell 71:145-152
99. Alcami A, Smith GL. 1995.Vaccinia, cowpox, and camelpox viruses encode soluble- interferon receptors with novel broad species specificity. J. Virol. 69:4633-4639
100. Alcami A, Koszinowski U. 2000. Viral mechanisms of immune evasion. Trends Microbiol. 8:410-418
101. Graham KA, Lalani AS, Macen JL, Ness TL, Barry M, et al. 1997. The T1/35kDa family of poxvirussecreted proteins bind chemokines and modulate leukocyte influx into virus-infected tissues. Virology 229:12-24
102. Calderara S, Xiang Y, Moss B. 2001. Orthopoxvirus IL-18 binding proteins: affinities and antagonist activities. Virology 279:22-26
103. Novick D, Kim S, Fantuzzi G, Reznikov L, Dinarello C, Rubenstein M. 1999. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 10:127-136
104. Xiang Y, Moss B. 1999. IL-18 binding and inhibition of interferon- induction by human poxvirus- encoded proteins. Proc. Natl. Acad. Sci. USA 96:11537-11542
105. Panus JF, Smith CA, Ray CA, Smith TD, Patel DD, Pickup DJ. 2002. Cowpox virus encodes a fifth member of the tumor necrosis factor receptor family: a soluble, secreted CD30 homologue. Proc. Natl. Acad. Sci. USA 99:8348-8353
106. Saraiva M, Smith P, Fallon P, Alcami A. 2002. Inhibition of type 1 cytokine-mediated inflammation by a soluble CD30 homologue encoded by ectromelia (mousepox) virus. J. Exp. Med. 196:829-839
107. Loparev VN, Parsons JM, Knight JC, Panus JF, Ray CA, et al. 1998. A third distinct tumor necrosis factor receptor of orthopoxviruses. Proc. Natl. Acad. Sci. USA 95:3786-3791
108. Smith KG, Strasser A, Vaux DL. 1996. CrmA expression in T lymphocytes of transgenic mice inhibits CD95 (Fas/APO-1)-transduced apoptosis, but does not cause lymphadenopathy or autoimmune disease. EMBO J. 15:5167-5176
109. Campbell JA, Trossman DS, Yokoyama WM, Carayannopoulos LN. 2007. Zoonotic orthopoxviruses encode a high-affinity antagonist of NKG2D. J. Exp. Med. 204:1311-1317
110. Dasgupta A, Hammarlund E, Slifka MK, Fruh K. 2007. Cowpox virus evades CTL recognition and inhibits the intracellular transport of MHC class I molecules. J. Immunol. 178:1654-1661
111. Li P,Wang N, Zhou D, Yee CS, Chang CH, et al. 2005. Disruption of MHC class II-restricted antigen presentation by vaccinia virus. J. Immunol. 175:6481-6488
112. Gubser C, Hue S, Kellam P, Smith GL. 2004. Poxvirus genomes: a phylogenetic analysis. J. Gen. Virol. 85:105-117
113. Inglesby TV, O'Toole T, Henderson DA, Bartlett JG, Ascher MS, et al. 2002. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287:2236-2252
114. Lucey D. 2005. Bacillus anthracis. In Mandell, Douglas and Bennett's Principle and Practice of Infectious Diseases, ed. G Mandell, J Bennett, R Dolin, pp. 2485-2491 Philadelphia: Elsevier. 6th ed.
115. Abramova FA, Grinberg LM, Yampolskaya OV,Walker DH. 1993. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc. Natl. Acad. Sci. USA 90:2291-2294
116. ChristopherGW,Cieslak TJ, Pavlin JA, Eitzen EM, Jr. 1997. Biological warfare. A historical perspective. JAMA 278:412-417
117. Bhatnagar R, Batra S. 2001. Anthrax toxin. Crit. Rev. Microbiol. 27:167-200
118. Brossier F, Mock M. 2001. Toxins of Bacillus anthracis. Toxicon 39:1747-1755
119. KoehlerTM.2002. Bacillus anthracis genetics and virulence gene regulation. Curr.Top. Microbiol. Immunol. 271:143-164
120. Mock M, Mignot T. 2003. Anthrax toxins and the host: a story of intimacy. Cell Microbiol. 5:15-23
121. Weiner MA,Read TD,Hanna PC, 2003, Identification and characterization of the gerH operon of Bacillus anthracis endospores: a differential role for purine nucleosides in germination, J. Bacteriol.,185,1462-1, 464
122. Levi MH, Pasculle AW, Dowling JN. 1987. Role of the alveolar macrophage in host defense and immunity to Legionella micdadei pneumonia in the guinea pig. Microb. Pathog. 2:269-282
123. Prince AS. 2003. The host response to anthrax lethal toxin: unexpected observations. J. Clin. Investig. 112:656-658
124. Duesbery NS,Webb CP, Leppla SH, Gordon VM, Klimpel KR, et al. 1998. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280:734-737
125. Park JM, Greten FR, Li ZW, Karin M. 2002. Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science 297:2048-2051
126. Welkos SL. 1991. Plasmid-associated virulence factors of nontoxigenic (pX01-) Bacillus anthracis. Microb. Pathog. 10:183-198
127. Beedham RJ, Turnbull PC,Williamson ED. 2001. Passive transfer of protection against Bacillus anthracis infection in a murine model. Vaccine 19:4409-4416
128. Brossier F, Levy M, Mock M. 2002. Anthrax spores make an essential contribution to vaccine efficacy. Infect. Immun. 70:661-664
129. Coulson NM, Fulop M, Titball RW. 1994. Bacillus anthracis protective antigen, expressed in Salmonella typhimurium SL 3261, affords protection against anthrax spore challenge. Vaccine 12:1395-1401
130. Ivins BE, Welkos SL, Knudson GB, Little SF. 1990. Immunization against anthrax with aromatic compound-dependent (Aro-) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen. Infect. Immun. 58:303-308
131. Pezard C, Weber M, Sirard JC, Berche P, Mock M. 1995. Protective immunity induced by Bacillus anthracis toxin-deficient strains. Infect. Immun. 63:1369-1372
132. Brand P, Haussinger K, Meyer T, Scheuch G, Schulz H, et al. 1999. Intrapulmonary distribution of deposited particles. J. Aerosol. Med. 12:275-284
133. Guidi-Rontani C, Levy M, Ohayon H, Mock M. 2001. Fate of germinated Bacillus anthracis spores in primary murine macrophages. Mol. Microbiol. 42:931-938
134. Guidi-Rontani C,Weber-Levy M, Labruyere E, Mock M. 1999. Germination of Bacillus anthracis spores within alveolar macrophages. Mol. Microbiol. 31:9-17
135. Ruthel G, Ribot WJ, Bavari S, HooverTA. 2004.Time-lapse confocal imaging of development of Bacillus anthracis in macrophages. J. Infect. Dis. 189:1313-1316
136. Cleret A, Quesnel-Hellmann A, Vallon-Eberhard A, Verrier B, Jung S, et al. 2007. Lung dendritic cells rapidly mediate anthrax spore entry through the pulmonary route. J. Immunol. 178:7994-8001
137. Ross J. 1957. Pathogenesis of anthrax following administration of spores by the respiratory route. J. Pathol. Bacteriol. 73:485-494
138. Heninger S, Drysdale M, Lovchik J, Hutt J, Lipscomb MF, et al. 2006.Toxin-deficient mutants of Bacillus anthracis are lethal in a murine model for pulmonary anthrax. Infect. Immun. 74:6067-6074
139. Lyons CR, Lovchik J, Hutt J, Lipscomb MF, Wang E, et al. 2004. Murine model of pulmonary anthrax: kinetics of dissemination, histopathology, and mouse strain susceptibility. Infect. Immun. 72:4801-4809
140. Drysdale M, Heninger S, Hutt J, Chen Y, Lyons CR, Koehler TM. 2005. Capsule synthesis by Bacillus anthracis is required for dissemination in murine inhalation anthrax. EMBO J. 24:221-227
141. Kozel TR, Murphy WJ, Brandt S, Blazar BR, Lovchik JA, et al. 2004. mAbs to Bacillus anthracis capsular antigen for immunoprotection in anthrax and detection of antigenemia. Proc. Natl. Acad. Sci. USA 101:5042-5047
142. Fellows PF, Linscott MK, Ivins BE, Pitt ML, Rossi CA, et al. 2001. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 19:3241-3247
143. Fritz DL, Jaax NK, Lawrence WB, Davis KJ, Pitt ML, et al. 1995. Pathology of experimental inhalation anthrax in the rhesus monkey. Lab. Investig. 73:691-702
144. Gleiser CA, Berdjis CC, Hartman HA, Gochenour WS. 1963. Pathology of experimental respiratory anthrax in Macaca mulatta. Br. J. Exp. Pathol. 44:416-426
145. Ivins BE, Pitt ML, Fellows PF, Farchaus JW, Benner GE, et al. 1998. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16:1141-1148
146. Vasconcelos D, Barnewall R, Babin M, Hunt R, Estep J, et al. 2003. Pathology of inhalation anthrax in cynomolgus monkeys (Macaca fascicularis). Lab. Investig. 83:1201-1209
147. Chand HS, Drysdale M, Lovchik J, Koehler TM, Lipscomb MF, Lyons CR. 2009. Discriminating virulence mechanisms among Bacillus anthracis strains by using a murine subcutaneous infection model. Infect. Immun. 77:429-435
148. Gill V, Cunha BA. 1997. Tularemia pneumonia. Semin. Respir. Infect. 12:61-67
149. Staples JE, Kubota KA, Chalcraft LG, Mead PS, Petersen JM. 2006. Epidemiologic and molecular analysis of human tularemia, United States, 1964-2004. Emerg. Infect. Dis. 12:1113-1118
150. Farlow J,Wagner DM, Dukerich M, Stanley M, Chu M, et al. 2005. Francisella tularensis in the United States. Emerg. Infect. Dis. 11:1835-1841
151. Kugeler KJ, Mead PS, Janusz AM, Staples JE, Kubota KA, et al. 2009. Molecular epidemiology of Francisella tularensis in the United States. Clin. Infect. Dis. 48:863-870
152. Butler T. 1979. Plague and tularemia. Pediatr. Clin. N. Am. 26:355-366
153. Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al. 2001. Tularemia as a biological weapon: medical and public health management. JAMA 285:2763-2773
154. Penn R. 2005. Francisella tularensis. In Mandell, Douglas and Bennett's Principle and Practice of Infectious Diseases, ed. G Mandell, J Bennett, R Dolin, pp. 2674-2685 Philadelphia: Elsevier. 6th ed.
155. Hornick RB, Eigelsbach HT. 1966. Aerogenic immunization of man with live tularemia vaccine. Bacteriol. Rev. 30:532-538
156. Fed. Drug. Admin. 2000. Code of Federal Regulations. Title 21, Vol.5, Pt. 314.Washington, DC: Gov. Print. Off. http://www1.va.gov/oro/apps/compendium/ Files/21CFR314.htm
157. Green SJ, Nacy CA, Schreiber RD, Granger DL, Crawford RM, et al. 1993. Neutralization of - interferon and tumor necrosis factor - blocks in vivo synthesis of nitrogen oxides from L-arginine and protection against Francisella tularensis infection in Mycobacterium bovis BCG-treated mice. Infect. Immun. 61:689-698
158. Green SJ, Scheller LF, MarlettaMA,SeguinMC,KlotzFW,et al. 1994. Nitric oxide: cytokine-regulation of nitric oxide in host resistance to intracellular pathogens. Immunol. Lett. 43:87-94
159. Polsinelli T, Meltzer MS, Fortier AH. 1994. Nitric oxide-independent killing of Francisella tularensis by IFN--stimulated murine alveolar macrophages. J. Immunol. 153:1238-1245
160. Sjostedt A, Conlan JW,North RJ. 1994. Neutrophils are critical for host defense against primary infection with the facultative intracellular bacterium Francisella tularensis in mice and participate in defense against reinfection. Infect. Immun. 62:2779-2783
161. Stenmark S, Sunnemark D, Bucht A, Sjostedt A. 1999. Rapid local expression of interleukin-12, tumor necrosis factor -and -interferon after cutaneous Francisella tularensis infection in tularemia-immune mice. Infect. Immun. 67:1789-1797
162. Conlan JW, Sjostedt A, North RJ. 1994. CD4+ and CD8+ T-cell-dependent and -independent host defense mechanisms can operate to control and resolve primary and secondary Francisella tularensis LVS infection in mice. Infect. Immun. 62:5603-5607
163. Yee D, Rhinehart-Jones TR, Elkins KL. 1996. Loss of either CD4+ or CD8+ T cells does not affect the magnitude of protective immunity to an intracellular pathogen, Francisella tularensis strain LVS. J. Immunol. 157:5042-5048
164. Chen W, Shen H, Webb A, KuoLee R, Conlan JW. 2003. Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensisLVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: Protection varies depending on pathogen virulence, route of exposure, and host genetic background. Vaccine 21:3690-3700
165. Wu TH, Hutt JA, Garrison KA, Berliba LS, Zhou Y, Lyons CR. 2005. Intranasal vaccination induces protective immunity against intranasal infection with virulent Francisella tularensis biovar A. Infect. Immun. 73:2644-2654
166. Ray HJ, Cong Y, Murthy AK, Selby DM, Klose KE, et al. 2009. Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A. Clin. Vaccine Immunol. 16:444-452
167. Kuo Lee R, Harris G, Conlan JW, Chen W. 2007. Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis. Vaccine 25:3781-3791
168. Wu T, Zsemlye J, Statom G, Hutt J, Schrader R, et al. 2009. Vaccination of Fischer 344 rats against pulmonary infections by Francisella tularensis type A strains. Vaccine 27:4684-4693